|
|
Volumn 95, Issue 22, 2003, Pages 1656-1657
|
|
Combinations of targeted therapies take aim at multiple pathways
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AG 858;
ALEMTUZUMAB;
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BORTEZOMIB;
BORTEZUMIB;
CANCER VACCINE;
CYTOTOXIC AGENT;
DNA;
GEFITINIB;
HEAT SHOCK PROTEIN;
IMATINIB;
IMMUNOMODULATING AGENT;
MONOCLONAL ANTIBODY;
RITUXIMAB;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
ADVANCED CANCER;
BREAST CANCER;
CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CARDIOTOXICITY;
CHRONIC MYELOID LEUKEMIA;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG CYTOTOXICITY;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG TARGETING;
DRUG TOLERABILITY;
HUMAN;
KIDNEY CARCINOMA;
LUNG CANCER;
LYMPHOMA;
MELANOMA;
METASTASIS;
MULTIPLE MYELOMA;
NOTE;
PRIORITY JOURNAL;
|
|
EID: 0345099347
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/95.22.1656 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|